

Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-50 (cancelled).

51. (New) A method comprising a use of mannan-binding lectin (MBL) for the treatment of a patient suffering from systemic inflammatory response syndrome (SIRS) and/or a patient in need of transplantation and/or for reducing the risk in a patient of acquiring SIRS.

52. (New) The method according to claim 51, wherein the patient is in need of a transplantation.

53. (New) The method according to claim 51, to prevent the patient from acquiring SIRS.

54. (New) The method according to claim 51, wherein the patient is critically ill, wherein a critically ill patient is a patient which has sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to disease or injury, a patient who is being operated and where complications supervene, and a patient who has been operated in a vital organ within the last week or subject to major surgery within the last week.

55. (New) The method according to claim 51, wherein said MBL treatment is administered to increase the survival rate in the intensive care unit (ICU).

56. (New) The method according to claim 51, wherein said MBL treatment is administered to reduce the time that a patient stays within the hospital, for example within the intense care unit.

57. (New) The method according to claim 54, wherein the patient suffers from post-surgical critical illness.

58. (New) The method according to claim 54, wherein the patient suffers from post-traumatic critical illness.

59. (New) The method according to claim 51, wherein the MBL polypeptide monomer is a mammalian polypeptide monomer.

60. (New) The method according to claim 59, wherein said mammalian MBL polypeptide monomer is a human polypeptide monomer.

61. (New) The method according to claim 51, wherein said MBL comprises oligomers, wherein said oligomers are preferably selected from the group of oligomers consisting of trimers, tetramers, pentamers and/or hexamers.

62. (New) The method according to claim 51, wherein the MBL comprises at least one mannan-binding lectin (MBL) polypeptide monomer, or at least one mannan-binding lectin (MBL) polypeptide oligomer comprising or at least one mannan-binding lectin (MBL) polypeptide monomer.

63. (New) The method according to claim 51, wherein MBL comprises at least one mannan-binding lectin (MBL) polypeptide oligomer comprising at least one mannan-binding lectin (MBL) polypeptide monomer.

64. (New) The method according to claim 51, wherein the medicament is used in such way that the blood MBL level in the patient is kept above 250 ng/ml.

65. (New) The method according to claim 51, wherein the medicament is used in such way that the blood MBL level in the patient is kept above 500 ng/ml.

66. (New) The method according to claim 51, wherein the medicament is used in such way that the blood MBL level in the patient is kept above 1000 ng/ml.

67. (New) The method according to claim 51, wherein the medicament is used in such way that the blood MBL level in the patient is kept between 1000 ng/ml and 2000 ng/ml.

68. (New) The method according to claim 51, wherein the medicament is administered to the individual prior to another treatment at ICUs.

69. (New) The method according to claim 51, wherein the medicament is administered to the individual simultaneously, sequentially or separately with another treatment.

70. (New) The method according to claim 51, wherein the medicament is administered to the individual prior to during or after said other treatment.

71. (New) The method according to claim 51, wherein the patient has MBL polypeptide serum levels below a predetermined minimum MBL polypeptide serum level, wherein the predetermined level is a concentration of 500 ng/ml.

72. (New) The method according to claim 51, wherein said treatment is to reduce the risk of a fatal outcome during intensive care treatment of an individual.